Annexon: Maintaining "Buy" Rating for Second C1q Inhibitor Advancement

Annexon maintains "Buy" rating for its second C1q inhibitor advancement in geographic atrophy. The company's therapeutic approach aims to inhibit the C1q protein, which is involved in the complement system and contributes to the progression of geographic atrophy. The second advancement has shown positive results in a phase 2 trial, supporting Annexon's therapeutic approach for this indication.